Acorda Therapeutics 3Q 2016 Earnings Update

Acorda Therapeutics reported 3Q 2016 net revenue of $128.8 million, representing 10% growth year-over-year, with Ampyra (dalfampridine) as a key revenue driver. The company reiterated 2016 net sales guidance of $475-$485 million and provided an intellectual property update regarding ongoing IPR proceedings with a decision expected in March 2017.